Vancive Medical Technologies and CareFusion Corporation announce an exclusive agreement in the United States, Canada and Mexico for the licensing and distribution of Vancives BeneHold Chlorhexidine Gluconate (CHG) antimicrobial Adhesive Technology for applications in vascular access.
Under the agreement, CareFusion will market Vancives unique antimicrobial adhesive technology used with transparent dressings that are ideally suited for protection of catheter insertion sites. The first product received 510(k) clearance from the Food and Drug Administration (FDA) in September 2012 and will be co-branded under CareFusions new ChloraShield brand.
We are excited about this collaboration, and believe it is an excellent opportunity to combine the unique capabilities of each company, says Howard Kelly, president and general manager of Vancive Medical Technologies. By bringing together the considerable infection prevention expertise at CareFusion and Vancives cutting-edge technologies, we will provide innovative solutions to the vascular access market.
CareFusion and Vancive are working together to develop a comprehensive line of dressing products that incorporate the BeneHold CHG antimicrobial Adhesive Technology to meet the specific needs associated with many types of vascular access procedures. CareFusion expects to commercialize these offerings during the companys fiscal third quarter, which begins in April.
The collaboration with Vancive Medical Technologies and the new ChloraShieldTM line of dressings are a perfect fit with our leadership in CHG products, says Jim Leitl, senior vice president and general manager of Medical Specialties at CareFusion. These innovative vascular access dressings extend our clinically differentiated infection prevention and vascular access product portfolios, allowing us to create greater value for our customers.
* BeneHold is a trademark of Avery Dennison Corporation. ChloraShield is a trademark of CareFusion Corporation.
Source: Vancive Medical Technologies, CareFusion Corp.